Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan;89(1):25-33.
doi: 10.1016/j.mayocp.2013.10.021.

Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol

Suzette J Bielinski  1 , Janet E Olson  2 , Jyotishman Pathak  2 , Richard M Weinshilboum  3 , Liewei Wang  4 , Kelly J Lyke  2 , Euijung Ryu  2 , Paul V Targonski  5 , Michael D Van Norstrand  6 , Matthew A Hathcock  2 , Paul Y Takahashi  5 , Jennifer B McCormick  7 , Kiley J Johnson  8 , Karen J Maschke  9 , Carolyn R Rohrer Vitek  8 , Marissa S Ellingson  8 , Eric D Wieben  10 , Gianrico Farrugia  11 , Jody A Morrisette  2 , Keri J Kruckeberg  12 , Jamie K Bruflat  12 , Lisa M Peterson  12 , Joseph H Blommel  12 , Jennifer M Skierka  12 , Matthew J Ferber  12 , John L Black  12 , Linnea M Baudhuin  12 , Eric W Klee  2 , Jason L Ross  13 , Tamra L Veldhuizen  8 , Cloann G Schultz  8 , Pedro J Caraballo  14 , Robert R Freimuth  2 , Christopher G Chute  2 , Iftikhar J Kullo  15
Affiliations

Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol

Suzette J Bielinski et al. Mayo Clin Proc. 2014 Jan.

Abstract

Objective: To report the design and implementation of the Right Drug, Right Dose, Right Time-Using Genomic Data to Individualize Treatment protocol that was developed to test the concept that prescribers can deliver genome-guided therapy at the point of care by using preemptive pharmacogenomics (PGx) data and clinical decision support (CDS) integrated into the electronic medical record (EMR).

Patients and methods: We used a multivariate prediction model to identify patients with a high risk of initiating statin therapy within 3 years. The model was used to target a study cohort most likely to benefit from preemptive PGx testing among the Mayo Clinic Biobank participants, with a recruitment goal of 1000 patients. We used a Cox proportional hazards model with variables selected through the Lasso shrinkage method. An operational CDS model was adapted to implement PGx rules within the EMR.

Results: The prediction model included age, sex, race, and 6 chronic diseases categorized by the Clinical Classifications Software for International Classification of Diseases, Ninth Revision codes (dyslipidemia, diabetes, peripheral atherosclerosis, disease of the blood-forming organs, coronary atherosclerosis and other heart diseases, and hypertension). Of the 2000 Biobank participants invited, 1013 (51%) provided blood samples, 256 (13%) declined participation, 555 (28%) did not respond, and 176 (9%) consented but did not provide a blood sample within the recruitment window (October 4, 2012, through March 20, 2013). Preemptive PGx testing included CYP2D6 genotyping and targeted sequencing of 84 PGx genes. Synchronous real-time CDS was integrated into the EMR and flagged potential patient-specific drug-gene interactions and provided therapeutic guidance.

Conclusion: This translational project provides an opportunity to begin to evaluate the impact of preemptive sequencing and EMR-driven genome-guided therapy. These interventions will improve understanding and implementation of genomic data in clinical practice.

Keywords: CAB; CAP; CDS; CGSL; CLIA; Clinical Genome Sequencing Laboratory; Clinical Laboratory Improvement Amendments; College of American Pathologists; Community Advisory Board; EMR; Electronic Medical Record and Genomics; FDA; Food and Drug Administration; NGS; PGL; PGRN; PGx; Personalized Genomics Laboratory; Pharmacogenomics Research Network; RIGHT; The Right Drug, Right Dose, Right Time—Using Genomic Data to Individualize Treatment; clinical decision support; eMERGE; electronic medical record; next-generation sequencing; pharmacogenomics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mayo Clinic Center for Individualized Medicine (CIM) Process for Clinical Implementation of Pharmacogenomic Rules
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348(6):529–537. - PubMed
    1. Weinshilboum R, Wang L. Pharmacogenomics: bench to bedside. Nat Rev Drug Disc. 2004;3(9):739–748. - PubMed
    1. Weinshilboum RM, Wang L. Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu Rev of Genomics Hum Genet. 2006;7:223–245. - PubMed
    1. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011;364(12):1144–1153. - PMC - PubMed
    1. U.S. Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labels. http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/....

Publication types

MeSH terms

Substances